-
1
-
-
34547459725
-
Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer
-
DOI 10.1592/phco.27.8.1125
-
Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-1144. (Pubitemid 47173659)
-
(2007)
Pharmacotherapy
, vol.27
, Issue.8
, pp. 1125-1144
-
-
Grandinetti, C.A.1
Goldspiel, B.R.2
-
2
-
-
60549098640
-
Sorafenib: A review of its use in advanced hepatocellular carcinoma
-
Keating GM, Santoro A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-240.
-
(2009)
Drugs
, vol.69
, pp. 223-240
-
-
Keating, G.M.1
Santoro, A.2
-
3
-
-
33845323729
-
Sunitinib
-
discussion 2267-2268.
-
Deeks ED, Keating GM. Sunitinib. Drugs 2006;66:2255-2266; discussion 2267-2268.
-
(2006)
Drugs
, vol.66
, pp. 2255-2266
-
-
Deeks, E.D.1
Keating, G.M.2
-
4
-
-
70249113967
-
-
[package insert]. West Haven, CT: Bayer Healthcare
-
Nexavar® (sorafenib) [package insert]. West Haven, CT: Bayer Healthcare, 2005.
-
(2005)
Nexavar® (Sorafenib)
-
-
-
6
-
-
70249146063
-
-
[package insert]. New York, NY: Pfizer Labs
-
Sutent® (sunitinib) [package insert]. New York, NY: Pfizer Labs, 2006.
-
(2006)
Sutent® (Sunitinib)
-
-
-
7
-
-
0035226814
-
Protein kinase-mediated signaling networks. Regulation and functional characterization
-
Reith AD. Protein kinase-mediated signaling networks. Regulation and functional characterization. Methods Mol Biol 2001;124:1-20.
-
(2001)
Methods Mol Biol
, vol.124
, pp. 1-20
-
-
Reith, A.D.1
-
8
-
-
33749238553
-
Discovery and development of sorafenib: A multikinase inhibitor for treating cancer
-
DOI 10.1038/nrd2130, PII NRD2130
-
Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844. (Pubitemid 44480537)
-
(2006)
Nature Reviews Drug Discovery
, vol.5
, Issue.10
, pp. 835-844
-
-
Wilhelm, S.1
Carter, C.2
Lynch, M.3
Lowinger, T.4
Dumas, J.5
Smith, R.A.6
Schwartz, B.7
Simantov, R.8
Kelley, S.9
-
9
-
-
44849093414
-
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
-
Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007;18(suppl 10):x3-x10.
-
(2007)
Ann Oncol
, vol.18
, Issue.SUPPL. 10
-
-
Christensen, J.G.1
-
10
-
-
33644847440
-
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
-
DOI 10.1200/JCO.2005.02.2194
-
Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35. (Pubitemid 46630490)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 25-35
-
-
Faivre, S.1
Delbaldo, C.2
Vera, K.3
Robert, C.4
Lozahic, S.5
Lassau, N.6
Bello, C.7
Deprimo, S.8
Brega, N.9
Massimini, G.10
Armand, J.-P.11
Scigalla, P.12
Raymond, E.13
-
11
-
-
37749052511
-
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma
-
Jain L, Gardner ER, Venitz J et al. Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal 2008;46:362-367.
-
(2008)
J Pharm Biomed Anal
, vol.46
, pp. 362-367
-
-
Jain, L.1
Gardner, E.R.2
Venitz, J.3
-
12
-
-
34247857540
-
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
-
DOI 10.1634/theoncologist.12-4-426
-
Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. The Oncologist 2007;12:426-437. (Pubitemid 46698720)
-
(2007)
Oncologist
, vol.12
, Issue.4
, pp. 426-437
-
-
Strumberg, D.1
Clark, J.W.2
Awada, A.3
Moore, M.J.4
Richly, H.5
Hendlisz, A.6
Hirte, H.W.7
Eder, J.P.8
Lenz, H.-J.9
Schwartzh, B.10
-
13
-
-
20044382799
-
Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
-
DOI 10.1200/JCO.2005.06.124
-
Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972. (Pubitemid 46202316)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.5
, pp. 965-972
-
-
Strumberg, D.1
Richly, H.2
Hilger, R.A.3
Schleucher, N.4
Korfee, S.5
Tewes, M.6
Faghih, M.7
Brendel, E.8
Voliotis, D.9
Haase, C.G.10
Schwartz, B.11
Awada, A.12
Voigtmann, R.13
Scheulen, M.E.14
Seeber, S.15
-
14
-
-
33645648696
-
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
-
Lathia C, Lettieri J, Cihon F et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-692.
-
(2006)
Cancer Chemother Pharmacol
, vol.57
, pp. 685-692
-
-
Lathia, C.1
Lettieri, J.2
Cihon, F.3
-
15
-
-
34548310428
-
Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors
-
DOI 10.1016/j.clinthera.2007.07.022, PII S0149291807002147
-
Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-1353. (Pubitemid 47348120)
-
(2007)
Clinical Therapeutics
, vol.29
, Issue.7
, pp. 1338-1353
-
-
Adams, V.R.1
Leggas, M.2
-
16
-
-
70249098383
-
The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011249 pharmacokinetics (PK) in Caucasian and Asian healthy subjects
-
abstract 553
-
Washington C, Eli M, Bello C et al. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011249 pharmacokinetics (PK) in Caucasian and Asian healthy subjects [abstract 553]. Proc Am Soc Clin Oncol 2003;22.
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Washington, C.1
Eli, M.2
Bello, C.3
-
17
-
-
33745148889
-
Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers
-
abstract
-
Bello C, Houk B, Sherman L et al. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers [abstract]. Proc Am Soc Clin Oncol 2005;23(16 suppl):3078.
-
(2005)
Proc Am Soc Clin Oncol
, vol.23
, Issue.16 SUPPL.
, pp. 3078
-
-
Bello, C.1
Houk, B.2
Sherman, L.3
-
18
-
-
33646204716
-
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
-
Richly H, Henning BF, Kupsch P et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-873.
-
(2006)
Ann Oncol
, vol.17
, pp. 866-873
-
-
Richly, H.1
Henning, B.F.2
Kupsch, P.3
-
19
-
-
33846020023
-
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib
-
DOI 10.1016/j.ejca.2006.08.032, PII S0959804906008033
-
Mross K, Steinbild S, Baas F et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43:55-63. (Pubitemid 46054474)
-
(2007)
European Journal of Cancer
, vol.43
, Issue.1
, pp. 55-63
-
-
Mross, K.1
Steinbild, S.2
Baas, F.3
Gmehling, D.4
Radtke, M.5
Voliotis, D.6
Brendel, E.7
Christensen, O.8
Unger, C.9
-
20
-
-
64649083367
-
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
-
Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-1805.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1800-1805
-
-
Miller, A.A.1
Murry, D.J.2
Owzar, K.3
-
21
-
-
34248585901
-
Sorafenib: Delivering a targeted drug to the right targets
-
Flaherty KT. Sorafenib: Delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007;7:617-626.
-
(2007)
Expert Rev Anticancer Ther
, vol.7
, pp. 617-626
-
-
Flaherty, K.T.1
-
22
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
DOI 10.1056/NEJMoa060655
-
Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
Negrier, S.7
Chevreau, C.8
Solska, E.9
Desai, A.A.10
Rolland, F.11
Demkow, T.12
Hutson, T.E.13
Gore, M.14
Freeman, S.15
Schwartz, B.16
Shan, M.17
Simantov, R.18
Bukowski, R.M.19
-
23
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
24
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
-
(2006)
Lancet
, vol.368
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
-
25
-
-
38549085315
-
Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis
-
Wu S, Chen JJ, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008;9:117-123.
-
(2008)
Lancet Oncol
, vol.9
, pp. 117-123
-
-
Wu, S.1
Chen, J.J.2
Kudelka, A.3
|